When Nuance Matters: The lesser known side of PD1 signaling

The inhibitory immunoreceptor PD1 is a major cancer immunotherapy target. Anti-PD1 blockade antibodies have become the standard of care for cancer patients, but the low response rate and associated immune related side effects necessitate a better understanding of PD1 mechanism. Best known to be expressed by T cells, PD1 transduces inhibitory signals to attenuate T cell response upon binding to its ligand PDL1. In this seminar I will share our ongoing studies on the unexpected nuances in the signaling mechanism of PD1.